成长主线热度回升，主板压力有点大

Market Overview - The A-share market exhibited a typical structural trend with "main board retreating after a rise, strong growth in the ChiNext, and widespread declines in individual stocks" [1] - The Shanghai Composite Index slightly fell by 0.15% to 3,864.18 points, while the Shenzhen Component Index rose by 1.02% to 12,907.83 points, and the ChiNext Index surged by 2.14% to 3,044.69 points [2] - Total trading volume for the day was 1.78 trillion yuan, a decrease of 28.8 billion yuan from the previous day, indicating pressure on heavyweight sectors and a focus on specific leading themes [1] Technical Analysis - The Shanghai Composite Index has faced resistance at the 60-day moving average (around 3,880 points) for three consecutive days, indicating significant short-term pressure [3] - The ChiNext Index has successfully filled the gap from November 20 and stabilized above the 3,000-point level [3] - Key observations include whether the main board can break through the 60-day line with increased volume and the sustainability of the AI and pharmaceutical sectors as leading themes [3] Industry and Hotspot Capture - The market has undergone a purification process, with funds highly concentrated on AI computing hardware (optical modules/CPO) and anti-influenza pharmaceuticals, while other themes have been marginalized [4] - This trend reflects an increase in market efficiency and a lower tolerance for errors, focusing solely on leading themes [4] AI Computing Hardware - The optical module/CPO sector continues to show strong performance, with companies like Zhongji Xuchuang (300308) reaching historical highs [5] - The driving factors include Meta's plans for large-scale procurement of Google TPUs, supply shortages of NVIDIA's Blackwell, and increased capital expenditure by Alibaba on AI cloud [5] - The market confirms that optical modules are essential for both GPU and TPU architectures, indicating a solid underlying logic and institutional-led market activity [5] Anti-Influenza Pharmaceuticals - The anti-influenza concept has seen a comprehensive surge, driven by the rapid increase in national influenza activity and a 237% weekly increase in the sales of Oseltamivir [6] - Companies such as Huaren Health (301408), Guangdong Wannianqing (301111), Renmin Tongtai (600829), and Ruikang Pharmaceutical (002589) have experienced significant gains [6] - The pharmaceutical sector combines event-driven dynamics with defensive attributes, allowing it to stand out in the growth theme [6]